Literature DB >> 25647750

Association of depressive and anxiety symptoms with 24-hour urinary catecholamines in individuals with untreated high blood pressure.

Nicola J Paine1, Lana L Watkins, James A Blumenthal, Cynthia M Kuhn, Andrew Sherwood.   

Abstract

OBJECTIVE: Depression and anxiety are considered risk factors for cardiovascular disease (CVD). The explanatory mechanisms, however, are still to be characterized. One proposed pathophysiological pathway is dysregulation of the autonomic nervous system, including heightened sympathetic nervous system activity. This study examined the relationship between symptoms of depression, anxiety, and sympathetic nervous system activity in individuals with untreated high blood pressure.
METHODS: A total of 140 participants with untreated high blood pressure (55% white, 38.5% female, mean [standard deviation] age = 45.5 [8.55] years) collected urine over a 24-hour period on 3 separate occasions. Urine samples were assayed for mean 24-hour epinephrine (EPI24) and norepinephrine excretion. Depressive symptoms were assessed using the Beck Depression Inventory, with anxiety symptoms assessed using the Spielberger State-Trait Anxiety Inventory.
RESULTS: Depression and anxiety scores were intercorrelated (r = 0.76, p < .001). EPI24 was positively correlated with anxiety (r = 0.20, p = .02) but not depression (r = 0.02, p = .77), whereas 24-hour urinary norepinephrine excretion was not correlated with anxiety (r = 0.10, p = .21) or with depression (r = 0.07, p = .39). Regression models, accounting for sex, age, body mass index, race, mean systolic ambulatory blood pressure, tobacco use, alcohol use, physical activity, and sleep efficiency confirmed that anxiety was associated with EPI24 excretion (p = .023) and that depressive symptoms were not (p = .54).
CONCLUSIONS: Anxiety was associated with heightened sympathoadrenal activity, suggesting a biological pathway through which anxiety could increase CVD risk. Anxiety and depression may confer increased CVD risk via different mechanisms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25647750      PMCID: PMC5119914          DOI: 10.1097/PSY.0000000000000144

Source DB:  PubMed          Journal:  Psychosom Med        ISSN: 0033-3174            Impact factor:   4.312


  71 in total

1.  What does heart disease have to do with anxiety?

Authors:  Joel E Dimsdale
Journal:  J Am Coll Cardiol       Date:  2010-06-29       Impact factor: 24.094

2.  Anxiety and risk of incident coronary heart disease: a meta-analysis.

Authors:  Annelieke M Roest; Elisabeth J Martens; Peter de Jonge; Johan Denollet
Journal:  J Am Coll Cardiol       Date:  2010-06-29       Impact factor: 24.094

3.  Role of cardiac disease severity in the predictive value of anxiety for all-cause mortality.

Authors:  Thomas Meyer; Ullrich Buss; Christoph Herrmann-Lingen
Journal:  Psychosom Med       Date:  2009-12-07       Impact factor: 4.312

4.  A comparison of overnight and 24 hour collection to measure urinary catecholamines.

Authors:  I R White; E J Brunner; J L Barron
Journal:  J Clin Epidemiol       Date:  1995-02       Impact factor: 6.437

5.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

6.  The effects of depressive symptoms on cardiovascular and catecholamine responses to the induction of depressive mood.

Authors:  Mark Hamer; Gohichi Tanaka; Hisayoshi Okamura; Akira Tsuda; Andrew Steptoe
Journal:  Biol Psychol       Date:  2006-07-24       Impact factor: 3.251

Review 7.  Determination of catecholamines in plasma and urine.

Authors:  Eric Grouzmann; Faiza Lamine
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2013-07-09       Impact factor: 4.690

8.  Association of anxiety disorders and depression with incident heart failure.

Authors:  Lauren D Garfield; Jeffrey F Scherrer; Paul J Hauptman; Kenneth E Freedland; Tim Chrusciel; Sumitra Balasubramanian; Robert M Carney; John W Newcomer; Richard Owen; Kathleen K Bucholz; Patrick J Lustman
Journal:  Psychosom Med       Date:  2014-01-16       Impact factor: 4.312

9.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

Review 10.  The HPA axis in major depression: classical theories and new developments.

Authors:  Carmine M Pariante; Stafford L Lightman
Journal:  Trends Neurosci       Date:  2008-07-31       Impact factor: 13.837

View more
  9 in total

Review 1.  Serotonin and Serotonin Transporters in the Adrenal Medulla: A Potential Hub for Modulation of the Sympathetic Stress Response.

Authors:  Rebecca L Brindley; Mary Beth Bauer; Randy D Blakely; Kevin P M Currie
Journal:  ACS Chem Neurosci       Date:  2017-04-13       Impact factor: 4.418

Review 2.  Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition.

Authors:  Borwin Bandelow; David Baldwin; Marianna Abelli; Blanca Bolea-Alamanac; Michel Bourin; Samuel R Chamberlain; Eduardo Cinosi; Simon Davies; Katharina Domschke; Naomi Fineberg; Edna Grünblatt; Marek Jarema; Yong-Ku Kim; Eduard Maron; Vasileios Masdrakis; Olya Mikova; David Nutt; Stefano Pallanti; Stefano Pini; Andreas Ströhle; Florence Thibaut; Matilde M Vaghi; Eunsoo Won; Dirk Wedekind; Adam Wichniak; Jade Woolley; Peter Zwanzger; Peter Riederer
Journal:  World J Biol Psychiatry       Date:  2016-07-15       Impact factor: 4.132

3.  Adrenal serotonin derives from accumulation by the antidepressant-sensitive serotonin transporter.

Authors:  Rebecca L Brindley; Mary Beth Bauer; L Anne Walker; Meagan A Quinlan; Ana M D Carneiro; Ji-Ying Sze; Randy D Blakely; Kevin P M Currie
Journal:  Pharmacol Res       Date:  2018-06-09       Impact factor: 7.658

4.  Experiences of Discrimination and Urinary Catecholamine Concentrations: Longitudinal Associations in a College Student Sample.

Authors:  Lydia K Homandberg; Thomas E Fuller-Rowell
Journal:  Ann Behav Med       Date:  2020-11-01

5.  Improvement in health-related quality of life after renal sympathetic denervation in real-world hypertensive patients: 12-month outcomes in the Global SYMPLICITY Registry.

Authors:  Ingrid Kindermann; Sonja Maria Wedegärtner; Felix Mahfoud; Joachim Weil; Nicole Brilakis; Julia Ukena; Sebastian Ewen; Dominik Linz; Martin Fahy; Giuseppe Mancia; Michael Böhm
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-05-07       Impact factor: 3.738

6.  Generalized Anxiety Disorder and Hypoglycemia Symptoms Improved with Diet Modification.

Authors:  Monique Aucoin; Sukriti Bhardwaj
Journal:  Case Rep Psychiatry       Date:  2016-07-14

7.  Association Between Depression, Anxiety, and Antidepressant Use With T-Wave Amplitude and QT-Interval.

Authors:  Mandy X Hu; Femke Lamers; Brenda W J H Penninx; Eco J C de Geus
Journal:  Front Neurosci       Date:  2018-06-05       Impact factor: 4.677

8.  Association Between Residential Greenness and Cardiovascular Disease Risk.

Authors:  Ray Yeager; Daniel W Riggs; Natasha DeJarnett; David J Tollerud; Jeffrey Wilson; Daniel J Conklin; Timothy E O'Toole; James McCracken; Pawel Lorkiewicz; Zhengzhi Xie; Nagma Zafar; Sathya S Krishnasamy; Sanjay Srivastava; Jordan Finch; Rachel J Keith; Andrew DeFilippis; Shesh N Rai; Gilbert Liu; Aruni Bhatnagar
Journal:  J Am Heart Assoc       Date:  2018-12-18       Impact factor: 5.501

Review 9.  Depression and Cardiovascular Disease: The Viewpoint of Platelets.

Authors:  Patrizia Amadio; Marta Zarà; Leonardo Sandrini; Alessandro Ieraci; Silvia Stella Barbieri
Journal:  Int J Mol Sci       Date:  2020-10-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.